Research programme: NR2B NMDA receptor antagonists - Evotec AG/ Janssen

Drug Profile

Research programme: NR2B NMDA receptor antagonists - Evotec AG/ Janssen

Alternative Names: ENS 102; EVT 100 series; EVT 102; NR2B-selective NMDA receptor antagonists; RO-631908

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Evotec AG
  • Class Phenols; Piperidines; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Neuropathic pain; Postoperative pain

Most Recent Events

  • 31 Dec 2011 Discontinued - Preclinical for Postoperative pain in Germany (IV)
  • 31 Dec 2011 Discontinued - Preclinical for Neuropathic pain in Germany (PO)
  • 31 Dec 2011 Discontinued - Preclinical for Alzheimer's disease in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top